Ajorlou Elham, Khosroushahi Ahmad Yari
Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Cancer Chemother Pharmacol. 2017 Feb;79(2):251-265. doi: 10.1007/s00280-016-3168-6. Epub 2016 Oct 15.
The dawn of the state-of-the-art methods of cancer treatments, nano-based delivery systems, has dispensed with the mainstream chemotherapy for being inadequate in yielding productive results and the numerous reported side effects. The popularity of this complementary approach in the course of the last two decades has been primarily attributed to its capacity to elevate the therapeutic index of anticancer drugs as well as removing the impassable delivery barriers in solid tumors with the minimal damage to the normal tissues.
The PubMed database was consulted to compile this review.
A wide range of minuscule organic and inorganic nanomaterials, with dimensions not exceeding hundred nanometers, has led to hope for cancer therapy to flare-up once again due to possessing a number of exclusive traits for passive and active tumor targeting, some of which are EPR effect, high interstitial pressure of tumor, overexpressed receptors and angiogenesis. Although a limited number of liposomal and polymer-based therapeutic nanoparticles have gained applicability, a vast number of nanoparticles are still being trailed in order to be fully developed.
This study provides an overview of the advantages/disadvantages of nanocarriers for cancer drug delivery.
癌症治疗的先进方法——基于纳米的递送系统的出现,摒弃了主流化疗方法,因为其在产生有效结果方面存在不足,且有大量报道的副作用。在过去二十年中,这种补充方法的流行主要归因于其提高抗癌药物治疗指数的能力,以及在对正常组织造成最小损害的情况下消除实体瘤中不可逾越的递送障碍的能力。
查阅PubMed数据库以编写本综述。
一系列尺寸不超过一百纳米的微小有机和无机纳米材料,由于具有许多用于被动和主动肿瘤靶向的独特特性,如增强渗透与滞留(EPR)效应、肿瘤的高间质压力、过表达的受体和血管生成等,再次燃起了癌症治疗的希望。尽管有限数量的基于脂质体和聚合物的治疗性纳米颗粒已获得应用,但仍有大量纳米颗粒正在进行追踪以便充分开发。
本研究概述了纳米载体用于癌症药物递送的优缺点。